ClinicalTrials.gg
CompletedNCT01811186Updated Mar 10, 2017Results posted

An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)

A Phase 4 interventional study of Oxycodone/naloxone in Chronic Pain, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Chronic Pain with a site in Korea, Republic of — 10 open to participants now, 11 under way, none of them phase 3. Chronic Pain · Korea, Republic of.

Enrollment
4th of 28
261 · median 76
Started
2012
the only one that year
Phase 4
3 of 36
none open now
Registered
5th of 36
by date

Among the 36 studies in Chronic Pain with a site in Korea, Republic of, this one is the 4th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 4, and was the 5th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

10 of the 36 studies in Chronic Pain with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Chronic Pain with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Objectives:

  1. Objective of main interest

    • To assess the drop-out rate caused by adverse event* after 6 weeks treatment
  2. Further objectives

    • To assess the drop-out rate caused by adverse event* after 1 week treatment
    • To assess the pain reduction rate after 6 weeks treatment from baseline
    • To assess the Euroquol (EQ-5D) quality of life
    • To assess physician's overall satisfaction
    • To assess subject's overall satisfaction
    • To assess safety
Read the detailed description

Study Design (Methodology):

This will be a single center, open-label, randomised, phase IV, exploratory interventional study to compare the efficacy and tolerability of current titration patterns and slow titration pattern with Targin® (Oxycodone/Naloxone) in the treatment of moderate to severe non-malignant chronic pain patients who are dissatisfied with their current analgesic medication World Health Organisation (WHO) step II analgesics).

Upon providing written informed consent, subject will be screened in the study and assessment will be performed at that time such as safety laboratory assessments, physical examination, vital sign, medical history taking, 24 hours pain intensity score. If the patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient will be randomized in a 1:1 ratio to allocate in Group A or Group B. Re-screening, study drug dose interruption is not allowed.

03

Conditions studied

  • Chronic Pain

Browse trials for

Keywords

  • moderate to severe non-malignant chronic pain
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 20 and \<80 years of age
  • Patients who have non-malignant chronic pain(≥90 days)
  • Patients who have moderate to severe pain intensity which is not controlled with non-strong opioid
  • Naïve patients for Oxycodone/Naloxone (Naïve patient defined as who did not treated for 90 days)
  • Naïve patients for strong opioid (Naïve patient defined as who did not treated for 90 days)
  • Patients who signed a written form

Exclusion criteria

Exclusion Criteria:

  • Women of , defined as all women physiologically capable of becoming pregnant.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
  • Patients with known to Oxycodone/Naloxone or to any of the
  • Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
  • Having used other drugs at the time of enrollment, or within 30 days of enrollment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
261 participants (actual)

Study arms

  • Other
    Group A

    Start oxycodone/naloxone 10/5mg b.i.d. titration-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.

    Drug: Oxycodone/naloxone

  • Other
    Group B

    Start oxycodone/naloxone 5/2.5mg b.i.d titration-\> 10/5mg b.i.d.-\>20/10mg b.i.d.-\>30/15mg b.i.d-\>40/20mg b.i.d.

    Drug: Oxycodone/naloxone

Interventions

  • DrugOxycodone/naloxone

    Drug pages: Oxycodone · Naloxone

    Oxycodone/naloxone titration

    Also known as: Targin

06

What researchers measure

Primary outcomes

  1. Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment

    To assess the drop-out rate caused by adverse event\* after 6 weeks treatment

    Time frame: 6 weeks

Secondary outcomes

  1. The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.

    The drop-out rate due to an adverse event after treatment (1 week) by treatment arm were summarized and presented as frequency and percentage, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.

    Time frame: 1 week

  2. The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.

    Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline to 6weeks. NRS score was measured from 0 (No pain) to 10(worst pain imaginable).

    Time frame: 6 weeks

  3. Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug

    EQ-5D to measure of health related quality of life should be answered as one of 3 levels about current condition for 5 dimensions and was calculated total average by giving a weighting on 3 level of answers (EQ-5D levels into 'no problems' (level 1) and 'problems' (level 2 and 3)). Table of scores by each level for EQ-5D items: mobility(level 1=0, level2=0.069,level 3=0.314), self care(level 1=0, level2=0.104,level 3=0.214), usual activities(level 1=0, level2=0.036,level 3=0.094), pain/discomfort (level 1=0, level2=0.,level 3=0.386) and anxiety/depression(level 1=0, level2=0.071,level 3=0.2) \*EQ-5D Total = 1 - 0.081 - (the score of the each level) - 0.269 (if at least one of level 3 presents) EQ-5D total score could be 0.919 in maximum and -0.594 in minimum if case all index indicates the level 3. So, if EQ-5D total score closed by "1" means that the healthy condition and high quality of life.

    Time frame: 6 weeks

  4. Assessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug

    Investigator's overall satisfaction after treatment (6 weeks) (Clinical Global Impression of Change Scale(CGIC) 7 point scale) by treatment arm were summarized and presented as frequency and proportion, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.

    Time frame: 6 weeks

  5. Assessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug

    At each visit, the subject assessed the overall satisfaction for efficacy by using the 7 point scale of Patient Global Impression of Change Scale(PGIC).

    Time frame: 6weeks

07

Results

Posted Mar 10, 2017

Participant flow

Safety set: 261 patients were enrolled. ITT set was 258, 3 patients of the 261 patients deviated from inclusion/exclusion criteria.

Participant flow — Overall Study
MilestoneStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d
Started132126
Completed6164
Not completed7162
Withdrew: Adverse event5438
Withdrew: Protocol violation56
Withdrew: Withdrawal by subject510
Withdrew: Lack of efficacy36
Withdrew: Lost to follow-up42

Outcome measures

PrimaryDrop-out Rate Caused by Adverse Event After 6 Weeks Treatment

To assess the drop-out rate caused by adverse event\* after 6 weeks treatment

Time frame:
6 weeks
Reported as:
Number · percentage of participants
Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment
percentage of participantsStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d.
Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment40.9130.16
SecondaryThe Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.

The drop-out rate due to an adverse event after treatment (1 week) by treatment arm were summarized and presented as frequency and percentage, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.

Time frame:
1 week
Reported as:
Number · percentage of participants
The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.
percentage of participantsStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d.
The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug.28.7919.84
SecondaryThe Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.

Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline to 6weeks. NRS score was measured from 0 (No pain) to 10(worst pain imaginable).

Time frame:
6 weeks
Reported as:
Mean · units on a scale
The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.
units on a scaleStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d.
The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study.-1.62 ± 1.90-1.48 ± 1.82
SecondaryChange of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug

EQ-5D to measure of health related quality of life should be answered as one of 3 levels about current condition for 5 dimensions and was calculated total average by giving a weighting on 3 level of answers (EQ-5D levels into 'no problems' (level 1) and 'problems' (level 2 and 3)). Table of scores by each level for EQ-5D items: mobility(level 1=0, level2=0.069,level 3=0.314), self care(level 1=0, level2=0.104,level 3=0.214), usual activities(level 1=0, level2=0.036,level 3=0.094), pain/discomfort (level 1=0, level2=0.,level 3=0.386) and anxiety/depression(level 1=0, level2=0.071,level 3=0.2) \*EQ-5D Total = 1 - 0.081 - (the score of the each level) - 0.269 (if at least one of level 3 presents) EQ-5D total score could be 0.919 in maximum and -0.594 in minimum if case all index indicates the level 3. So, if EQ-5D total score closed by "1" means that the healthy condition and high quality of life.

Time frame:
6 weeks
Reported as:
Mean · units on a scale
Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug
units on a scaleStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d.
Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug0.14 ± 0.260.07 ± 0.22
SecondaryAssessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug

Investigator's overall satisfaction after treatment (6 weeks) (Clinical Global Impression of Change Scale(CGIC) 7 point scale) by treatment arm were summarized and presented as frequency and proportion, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.

Time frame:
6 weeks
Reported as:
Number · participants
Assessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
participantsStart Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.d
Very much improved22
Much improved2730
Minimally improved4843
No change514
Minimally worse00
Much worse00
very much worse00
SecondaryAssessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug

At each visit, the subject assessed the overall satisfaction for efficacy by using the 7 point scale of Patient Global Impression of Change Scale(PGIC).

Time frame:
6weeks
Reported as:
Number · participants
Assessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug
participantsStart Oxycodone/Naloxone 10/5mg b.i.d.Start Oxycodone/Naloxone 5/2.5mg b.i.d.
Very much improved22
Much improved2428
Minimally improved4442
No change1116
Minimally worse01
Much worse10
Very much worse00

Adverse events

Collected over Safety set: Safety set included data obtained from all subjects who administered at least one dose of the study drug. Patients were followed by 6 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Start Oxycodone/Naloxone 10/5mg b.i.d—0/133 (0%)115/133 (86.5%)
Start Oxycodone/Naloxone 5/2.5mg b.i.d—2/128 (1.6%)104/128 (81.3%)
Most frequent serious events
Most frequent serious events
EventStart Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.d
Duodenal stenosisGastrointestinal disorders0/1331/128
InflammationGeneral disorders0/1331/128
Femoral neck fractureInjury, poisoning and procedural complications0/1331/128
Most frequent other events
Showing 10 of 46
Most frequent other events
EventStart Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.d
NauseaGastrointestinal disorders52/13346/128
DizzinessNervous system disorders32/13329/128
SomnolenceNervous system disorders21/13326/128
vomitingGastrointestinal disorders27/13316/128
ConstipationGastrointestinal disorders24/13321/128
PruritusSkin and subcutaneous tissue disorders20/13317/128
HeadacheNervous system disorders15/1338/128
UrticariaSkin and subcutaneous tissue disorders7/1330/128
InsomniaPsychiatric disorders6/1332/128
DyspepsiaGastrointestinal disorders5/1332/128

Baseline characteristics

Safety set: 261 ITT set: 258(3 patients were deviated inclusion/exclusion criteria among 261)

Age, Categorical
Age, Categorical(Participants)Start Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.dTotal
<=18 years000
Between 18 and 65 years7764141
>=65 years5562117
Age, Continuous
Age, Continuous(years)Start Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.dTotal
Mean60.63 ± 9.6961.15 ± 11.9460.88 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)Start Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.dTotal
Female8184165
Male514293
Region of Enrollment
Region of Enrollment(participants)Start Oxycodone/Naloxone 10/5mg b.i.dStart Oxycodone/Naloxone 5/2.5mg b.i.dTotal
Korea, Republic of132126258
08

Study locations

1 site
  • AMC
    Seoul, Korea, Republic of
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jan 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2013
First posted
Mar 14, 2013
Start
Dec 2012
Primary completionActual
Jan 2014
CompletionActual
Jun 2014
Results first posted
Mar 10, 2017
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01811186
Responsible party
Sponsor
First posted
Mar 14, 2013
Start date
Dec 2012
Primary completion
Jan 2014
Completion
Jun 2014
Results posted
Mar 10, 2017
Last update
Mar 10, 2017

Study contacts

Hoseong Lee, Dr.
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxycodone · Naloxone

Start the discussion